孟鲁司特钠治疗小儿过敏性紫癜的效果观察

Effects of Montelukast Sodium on Henoch-Schonlein Purpura in Children

目的:探究孟鲁司特钠治疗小儿过敏性紫癜(HSP)的临床效果,为小儿HSP的治疗提供药物指导。方法:选取2017年1月至2019年1月于九江市儿童医院接受治疗的214例HSP患儿为受试对象,按照入院顺序随机分为观察组与对照组各107例。对照组予以常规治疗,观察组在其基础上服用孟鲁司特钠进行治疗。比较两组患者的症状消失时间(皮肤紫癜、腹痛、关节肿痛)及治疗前、治疗1个月后血清免疫学指标[白介素-6(IL-6)、血清免疫球蛋白A(IgA)]、尿蛋白指标[尿微量白蛋白(ALB)、β2-微球蛋白(β2-MG)]的变化情况及治疗过程中的不良反应发生率。结果:治疗1个月后,两组患者皮肤紫癜、腹痛、关节肿痛等症状均得到有效改善,且观察组症状消失时间明显短于同期对照组(P<0.05),两组患者IL-6、IgA、ALB、β2-MG水平较治疗前均显著下降,且观察组明显低于对照组(P<0.05),治疗过程中两组患者不良反应发生率差异无统计学意义(P>0.05)。结论:孟鲁司特钠可明显改善小儿HSP症状,能有效缓解病症,且无明显不良反应,安全性高。

Objective:To explore the clinical effects of montelukast sodium in the treatment of Henoch-schonlein purpura(HSP)in children and provide drug guidance for the treatment of HSP in children.Methods:A total of 214 children patients with HSP who were treated in Jiujiang Children's Hospital from January 2017 to January 2019 were enrolled in the study.They were randomly divided into observation group and control group according to the order of admission,with 107 cases in each group.Control group was given routine treatment,and observation group was treated with montelukast sodium on this basis.The disappearance times of symptoms(skin purpura,abdominal pain,joint swelling and pain)and serum immunological indicators[interleukin-6(IL-6),serum immunoglobulin A(IgA)],urine protein indexes[urine microalbumin(ALB),β2-microglobulin(β2-MG)]before and after 1 month of treatment and incidence rate of adverse reactions during treatment were compared between the two groups.Results:After 1 month of treatment,the symptoms of skin purpura,abdominal pain and joint swelling and pain were effectively improved in the two groups,and the disappearance times of symptoms in observation group were significantly shorter than those in control group(P<0.05).The levels of IL-6,IgA,ALB andβ2-MG in the two groups were significantly lower than those before treatment,and the levels in observation group were significantly lower than those in control group(P<0.05).There was no significant difference in the incidence rate of adverse reactions between the two groups during treatment(P>0.05).Conclusion:Montelukast sodium can significantly improve the symptoms of HSP in children,can effectively alleviate the disease,and has no obvious adverse reactions and high safety.